Tempus AI AI Access Timeline
Reviewed Strategic Signal records on Tempus AI’s AI access relationships, rights, and disclosed economics.
These selected timelines include reviewed registry records that explicitly name each organization in a participant field. A product, affiliate, or parent name alone does not establish participation. Coverage reflects Strategic Signal’s research sample. Records are ordered by original announcement date. A record may reflect later amendments or evidence updates.
Oct 23, 2026 · Data-rights qualified
Tempus AI → Bristol Myers Squibb
Certain multimodal records from Tempus AI's de-identified oncology dataset, licensed to Bristol Myers Squibb for analysis and use with Pathos Foundry in therapeutic development.
Tempus AI role · Provider / asset owner
- Provider / asset owner — Tempus AI
- AI recipient — Bristol Myers Squibb
- Strategic buyer or operator — Bristol Myers Squibb
Recorded status · agreement disclosed active term. Last reviewed Oct 27, 2026.
Access · corpus delivery. Training rights · not disclosed.
Disclosed economics · $137.5 million in aggregate fixed payments, invoiced quarterly over the term; realized cash receipts are not verified. Scope · Contractual consideration covers the oncology data license, Lens access, and related analysis and research services; no allocation among those components is disclosed.
Evidence
Oct 23, 2026 · Data-rights qualified
Tempus AI → Pathos AI
Up to 500,000 de-identified patient records covering Alzheimer's disease and other specified neurological conditions, targeted for delivery at 100,000 records per year over five years with update availability.
Tempus AI role · Provider / asset owner
- Provider / asset owner — Tempus AI
- AI recipient — Pathos AI
- Strategic buyer or operator — Pathos AI
Recorded status · agreement disclosed active term. Last reviewed Oct 27, 2026.
Access · corpus delivery. Training rights · not disclosed.
Disclosed economics · Up to $55 million: $50 million at $100 per delivered record plus $5 million for availability of record updates; realized cash receipts depend on delivery and are not verified. Scope · The filing separately identifies record-license fees and update availability; no standalone value is assigned to the Tempus Agent.
Evidence
Apr 23, 2025 · Data-rights qualified
Tempus AI → Pathos AI
A de-identified multimodal oncology dataset licensed for a foundation-model development program.
Tempus AI role · Provider / asset owner
- Provider / asset owner — Tempus AI
- AI recipient — Pathos AI
- Strategic buyer or operator — Pathos AI
Recorded status · agreement disclosed; current payment performance not verified. Last reviewed Sep 16, 2026.
Access · training. Training rights · permitted.
Disclosed economics · $200m data-license fees over three years, including $50m upfront payable. Up to 50% may be settled in Pathos preferred shares. Separate $35m flows run from AstraZeneca to Tempus and Tempus to Pathos. Scope · contractually identified data license fees within broader arrangement
Evidence
- Form 8-K filed April 23, 2025, Item 8.01 · primary
Nov 3, 2023 · Data-rights qualified
Tempus AI → Recursion Pharmaceuticals
Tempus's proprietary de-identified patient-centric multimodal oncology database of clinical and molecular records, originally described by Recursion as more than 20 petabytes, licensed for therapeutic-development AI/ML use subject to unique-record caps and retention limits.
Tempus AI role · Provider / asset owner
- Provider / asset owner — Tempus AI
- AI recipient — Recursion Pharmaceuticals
- Strategic buyer or operator — Recursion Pharmaceuticals
Recorded status · active amended six year license. Last reviewed Sep 29, 2026.
Access · training, post training. Training rights · permitted.
Disclosed economics · The 2026 amendment sets $14 million annual license fees on each of the third, fourth and fifth anniversaries, at least $4 million of each payable in cash and the remainder in cash and/or Recursion shares. The original 2023 deal disclosed up to $160 million over five years. Scope · $42 million of amended third-through-fifth anniversary license fees is explicitly disclosed; amounts already paid under the original schedule and the economic effect of the reduced unique-record cap are not restated here.